Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register

Lignende værker

• No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
  af: Lunt, Mark, et al.
  Udgivet: (2010)
• Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
  af: Soliman, Moetaza M, et al.
  Udgivet: (2011)
• Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
  af: Low, Audrey S. L., et al.
  Udgivet: (2016)
• Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti–tumor necrosis factor therapies
  af: Saad, Amr A, et al.
  Udgivet: (2010)
• Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
  af: Saad, Amr A, et al.
  Udgivet: (2009)